How biopharma facilities are cutting water, buffer, and solvent waste

Read time: 7 minutes

Sustainable bioprocessing filtration has moved from an aspirational goal to an operational priority as the scale and cost of water, buffer, and solvent consumption in biopharma manufacturing come under increasing scrutiny. Water for injection (WFI) and purified water underpin nearly every downstream operation, from chromatography buffer preparation to equipment cleaning, and the resources required to produce them are substantial. Facilities addressing this challenge most effectively are those applying closed-loop strategies: recycling buffers, recovering solvents, and reclaiming process water rather than treating every stream as single-use waste.

Key takeaways

• Water accounts for approximately 95% of the components used in biopharma downstream processing, making water management the largest single lever for reducing process mass intensity.
• Buffer recycling during the equilibration phase of Protein A chromatography has demonstrated reductions of close to 50% in buffer consumption for that phase, with no effect on antibody yield or purity.
• Inline buffer dilution from concentrated stocks reduces facility footprint, WFI consumption, and the number of preparation and storage vessels required.
• Organic solvent nanofiltration offers a lower-energy alternative to distillation for recovering solvents such as acetonitrile from reversed-phase chromatography eluents.
• Process water reclamation through multi-stage membrane filtration can recover non-contact water streams for reuse within validated good manufacturing practices (GMP) frameworks.

Water use and process mass intensity in biopharma downstream processing

Biopharmaceutical manufacturing is one of the most water-intensive industrial processes. Water requirements of approximately 65 liters per gram of produced biopharmaceutical agent have been reported, with water comprising roughly 95% of the total mass used in downstream processing. That water takes the form of WFI and purified water used to prepare the many buffer solutions required across multiple chromatography steps. Downstream processing costs account for more than 80% of total biopharmaceutical manufacturing expense, and buffer management sits at the center of that burden.

Process mass intensity (PMI), which captures the total mass of water, raw materials, and consumables required to produce one kilogram of active pharmaceutical ingredient, has emerged as the standard metric for assessing the environmental efficiency of biologics manufacturing. Research on biologics PMI benchmarking established that PMI, originally developed for small molecules, applies directly to biopharmaceutical production and can be used to benchmark water and material efficiency across facilities and process trains.

The scale of the problem grows with the market. Buffer volumes are product mass-based, meaning that as upstream titers increase, downstream buffer demand scales proportionally. A 2023 modeling study found that buffer management strategy alone could drive PMI reductions of up to 90% between the best and worst scenarios evaluated at 2,000-liter scale. Buffers also occupy approximately 20% of a facility's physical footprint, comparable to the entire cell culture process area, making the economic and spatial case for reduction equally compelling.

Buffer management strategies: recycling, inline dilution, and WFI reduction

Buffer recycling represents one of the most direct routes to reducing WFI consumption in downstream operations. A 2025 peer-reviewed study implemented chromatography buffer recycling during the equilibration phase of Protein A chromatography for monoclonal antibody purification, demonstrating reductions of close to 50% in buffer consumption for that phase, with no changes in antibody yield or purity. The equilibration phase requires large volumes of buffer to condition the chromatography resin before each loading cycle, and the buffer exiting the column during this phase retains closely matched pH and conductivity to the incoming feed, making it amenable to recovery.

For solvent-based pharmaceutical processes, recycling by re-distillation has been established practice for decades. For aqueous buffer systems, the concept has been slower to develop, partly because the quality control requirements for recycled WFI-based buffers in a GMP environment are more complex to validate. Demonstrating that recycled buffers meet the same pH, conductivity, and bioburden specifications as freshly prepared material throughout the intended reuse cycles is a prerequisite for regulatory acceptance.

Inline buffer dilution (IBD) offers a complementary approach that reduces WFI consumption through concentrate-based preparation. In IBD, buffer concentrates, typically prepared at 10-fold strength, are diluted with water directly into the process line rather than prepared as full-volume batches in large stainless steel tanks. Inline dilution reduces the total volume of WFI consumed per batch, eliminates the need for large dedicated buffer preparation vessels, and enables greater use of single-use bioprocess bags. Facilities applying advanced analytics and digital integration to buffer skid control can run these systems within a closed-loop feedback framework, automatically adjusting concentrate feed ratios to maintain target specifications.

Solvent recovery chromatography: organic solvent nanofiltration vs distillation

Reversed-phase chromatography, used as a polishing step for peptides, insulin, and small biopharmaceutical proteins, generates eluent streams containing organic solvents, including acetonitrile, ethanol, and isopropanol mixed with aqueous buffer. These streams represent both a waste disposal challenge and a recovery opportunity. Traditional solvent recovery relies on distillation, which is effective but energy-intensive and potentially damaging to temperature-sensitive compounds.

Organic solvent nanofiltration (OSN) has emerged as a low-energy membrane-based alternative for solvent recovery and exchange. A 2024 review on solvent recovery via nanofiltration described OSN's application across active pharmaceutical ingredient concentration, solvent exchange, and solvent recovery, noting that a GMP-compliant mobile OSN pilot plant had successfully recovered more than 10 tons of active pharmaceutical ingredient from a methanol-based distillation residue over six months. OSN membranes operate at room temperature under applied pressure, offering reduced energy consumption and minimal thermal stress on recovered compounds compared with distillation.

SOURCE